Fig 3.

Adhesion molecule (AM) expression levels in the cerebrospinal fluid (CSF) of natalizumab (NZB)-treated patients and controls. (a) Intercellular adhesion molecule-1 (ICAM-1), (b) leucocyte function antigen-1 (LFA-1), (c) alpha-4 and (d) beta-1 median fluorescence intensity (MFI) levels of CD4 (small squares) and CD8 (large squares) T cells in the CSF of NZB-treated MS patients (n = 12), patients with non-inflammatory neurological disease (NIND) (n = 10) and newly diagnosed multiple sclerosis (MS) patients (MSneo, n = 5) were compared. Bars represent 95% confidence interval (CI); n.s. = not significant.]